Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart plus etoricoxib as first-line therapy in acute gouty arthritis
ChiCTR2600127542Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of genakumab in acute gout flare, sponsored by The First Hospital of Jilin University. Primary endpoints: Pain response rate at 72 hours, Gout recurrence rate within 12 weeks and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
acute gout flare
Beyond the preview
Go deeper on ChiCTR2600127542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127542.